Adamis Pharmaceuticals, a biopharmaceutical company developing therapeutics for respiratory diseases and cancer, completed the acqusition of DMK Pharmaceuticals, a privately held, clinical-stage neuroscience company. Financial terms were not disclosed. “Last fall, we initiated a process to explore strategic alternatives for the company with the goal of maximizing stockholder value. After engaging in a thorough process of exploring potential alternatives and transactions, we believe a merger with DMK is the best path forward for Adamis and the strategy that has the potential to deliver significant value to Adamis’ shareholders. I believe by combining Adamis’ commercial products and development infrastructure with DMK’s clinical-stage programs and library of small molecules, under Dr. Versi’s leadership, the new company will have the potential to develop multiple groundbreaking treatments and ultimately grow shareholder value,” David J. Marguglio, Adamis CEO.